Dr Reddys hopes to finish Phase 3 trials of Covid-19 vaccine by March-May

Dr Reddys Laboratories on Wednesday said the Phase 3 trials of Russia’s Sputnik V vaccine for Covid-19 in India to be conducted by it are expected to be completed by the end of March depending on approvals and data validation. The city-headquartered drug maker, which has received approval from the Drug Control General of India (DCGI) for conducting human clinical trials of Sputnik V, was expected to complete the Phase 2 trials by December, Dr Reddys Chief Executive Officer Erez Israeli said.

“Phase-3, we should finish somewhere by March and then of course it depends on the ability to compile the data, obtain the approvals etc. It can be as early as end of March or April /May and beyond. It depends on the results. Its a combination of phase-2, global phase-3 and phase-3 in India,” he told reporters here after announcing the company’s Q2 results.

He said the company needed to engage 100 and 1,400 volunteers for Phase 2 and 3 trials respectively.

Dr. Reddys and Russian Direct Investment Fund (RDIF), Russias sovereign wealth fund, entered into a partnership last month to conduct clinical trials of Sputnik V and its distribution in India.

As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddys upon regulatory approval in India.

On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the worlds first registered vaccine against Covid-19 based on the human adenoviral vectors platform. Sputnik V is currently undergoing phase 3 clinical trials in Russia and the proposed number of subjects is 40,000.

Related Posts

  • Pharma
  • July 16, 2025
  • 75 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

  • Pharma
  • July 16, 2025
  • 17 views
Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon. Shares of pharmaceutical companies traded flat on Wednesday, July…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Famous Vaidyaratnam Ayurveda Clinic in Delhi is now more Accessible to Patients

Famous Vaidyaratnam  Ayurveda  Clinic in Delhi is now more Accessible to Patients